- Home
- SNDX vs FPF Comparison
SNDX vs FPF Comparison
Compare SNDX & FPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- FPF
- Stock Information
- Founded
- SNDX 2005
- FPF 2013
- Country
- SNDX United States
- FPF United States
- Employees
- SNDX N/A
- FPF N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- FPF Trusts Except Educational Religious and Charitable
- Sector
- SNDX Health Care
- FPF Finance
- Exchange
- SNDX Nasdaq
- FPF Nasdaq
- Market Cap
- SNDX 1.1B
- FPF 1.1B
- IPO Year
- SNDX 2016
- FPF N/A
- Fundamental
- Price
- SNDX $9.60
- FPF $18.79
- Analyst Decision
- SNDX Strong Buy
- FPF
- Analyst Count
- SNDX 11
- FPF 0
- Target Price
- SNDX $34.18
- FPF N/A
- AVG Volume (30 Days)
- SNDX 2.0M
- FPF 186.7K
- Earning Date
- SNDX 07-31-2025
- FPF 01-01-0001
- Dividend Yield
- SNDX N/A
- FPF 8.08%
- EPS Growth
- SNDX N/A
- FPF N/A
- EPS
- SNDX N/A
- FPF N/A
- Revenue
- SNDX $43,722,000.00
- FPF N/A
- Revenue This Year
- SNDX $426.77
- FPF N/A
- Revenue Next Year
- SNDX $98.31
- FPF N/A
- P/E Ratio
- SNDX N/A
- FPF N/A
- Revenue Growth
- SNDX N/A
- FPF N/A
- 52 Week Low
- SNDX $8.58
- FPF $13.91
- 52 Week High
- SNDX $25.07
- FPF $18.09
- Technical
- Relative Strength Index (RSI)
- SNDX 48.99
- FPF 63.58
- Support Level
- SNDX $8.59
- FPF $18.70
- Resistance Level
- SNDX $10.01
- FPF $18.93
- Average True Range (ATR)
- SNDX 0.54
- FPF 0.13
- MACD
- SNDX 0.10
- FPF -0.00
- Stochastic Oscillator
- SNDX 71.48
- FPF 72.38
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.